

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Reproductive Health Science Limited
ABN	84 010 126 708

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Michelle Fraser
Date of last notice	8 April 2014

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	ML Fraser Nominees Pty Ltd ATF the Michelle Fraser Family Trust
Date of change	31 May 2016
No. of securities held prior to change	<u>Indirect</u> <ul style="list-style-type: none">• 351,719 Ordinary Fully Paid Shares• 900,000 Unlisted Options exercisable at \$0.25, expiring 31 December 2016.• 900,000 Unlisted Options exercisable at \$0.30, expiring 31 December 2016.• 900,000 Unlisted Options exercisable at \$0.35, expiring 31 December 2016.

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Class	Unlisted Options
Number acquired	<p>Indirect</p> <ul style="list-style-type: none"> • 1,500,000 Unlisted Options exercisable at \$0.21, expiring 31 May 2020. • 1,500,000 Unlisted Options exercisable at \$0.25, expiring 31 May 2020. <p>The above options are only exercisable on or after 1 January 2017 and will expire early if any of the existing options (expiring 31 December 2016) are exercised.</p>
Number disposed	Nil
Value/Consideration <small>Note: If consideration is non-cash, provide details and estimated valuation</small>	Nil consideration. Options provided as part an incentive based remuneration package for the Managing Director.
No. of securities held after change	<p><u>Indirect</u></p> <ul style="list-style-type: none"> • 351,719 Ordinary Fully Paid Shares • 900,000 Unlisted Options exercisable at \$0.25, expiring 31 December 2016. • 900,000 Unlisted Options exercisable at \$0.30, expiring 31 December 2016. • 900,000 Unlisted Options exercisable at \$0.35, expiring 31 December 2016. • 1,500,000 Unlisted Options exercisable at \$0.21, commencing 1 January 2017 and expiring 31 May 2020. • 1,500,000 Unlisted Options exercisable at \$0.25, commencing 1 January 2017 and expiring 31 May 2020.
Nature of change <small>Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back</small>	Issue of Unlisted Options in accordance with a resolution passed at the Company's Annual General Meeting held 25 May 2016.

+ See chapter 19 for defined terms.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change <small>Note: Details are only required for a contract in relation to which the interest has changed</small>	
Interest acquired	
Interest disposed	
Value/Consideration <small>Note: If consideration is non-cash, provide details and an estimated valuation</small>	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Not applicable
If so, was prior written clearance provided to allow the trade to proceed during this period?	Not applicable
If prior written clearance was provided, on what date was this provided?	Not applicable

⁺ See chapter 19 for defined terms.